3 citations
,
January 2022 in “Scientific Reports” This study found that SAMiRNA-AR68, a nanomedicine targeting androgen receptor mRNA, increased hair counts in androgenetic alopecia patients with no observed side effects.
1 citations
,
July 2022 in “JEADV Clinical Practice” This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.
December 2025 in “Clinical & Experimental Dermatology and Therapies” This study reported that Cosmerna ARI significantly improved androgenetic alopecia in Europeans over a 6-month period compared to a placebo, according to a double-blind, randomized, placebo-controlled clinical trial.
June 2026 in “Expert Opinion on Pharmacotherapy” This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.
November 2024 in “EMJ Dermatology” In clinical studies, inhibiting androgen receptor expression using CosmeRNA ARI SAMiRNA micelles effectively treated androgenetic alopecia by significantly increasing hair growth, as reported in this research.